Biotech funding on track to bounce back
It’s not over yet, but 2003 already looks like a banner year for biotechnology funding in the United States, according to a survey released yesterday by the accounting firm Ernst & Young.
Popping a pill could fix gene defect
Simply popping a pill might be enough to overcome the type of genetic defect responsible for many cases of cystic fibrosis, muscular dystrophy and haemophilia. An experimental drug called PTC124 produces a working protein even though the gene remains defective.
Monsanto Overhauling Businesses
Monsanto, the world’s leading agricultural biotechnology company, says it is abandoning efforts to produce pharmaceuticals in genetically engineered crops to focus on businesses that could pay off sooner.
Cloning Remains a Meaty Issue
The Food and Drug Administration soon will decide whether the meat in your Philly cheese steak or your barbecue spareribs could come from a cloned animal.
Because of safety concerns, the FDA has barred the handful of companies that clone farm animals from selling them for meat. But since early this year, those companies have been submitting data — generated by independent research firms — to the FDA.